Stock Events

Stock Events

Vaxil Bio 

$0.031000
3
-$0.08-71.89% Friday 19:45

Statistics

Day High
0.028
Day Low
0.028
52W High
0.5
52W Low
0.0021
Volume
424
Avg. Volume
153
Mkt Cap
123,504
P/E Ratio
0.05
Dividend Yield
-
Dividend
-

Earnings

30SepExpected
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Q1 2021
Q2 2021
-0
-0
-0
-0
Expected EPS
N/A
Actual EPS
-0.0014

Financials

-Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
0Revenue
383,169.77Net Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novavax
NVAX
Mkt Cap1.53B
Novavax is a competitor because it also focuses on developing vaccines for infectious diseases, similar to Vaxil Bio's focus on immunotherapy and vaccines.
Moderna
MRNA
Mkt Cap55.09B
Moderna is involved in mRNA-based vaccines, competing in the innovative vaccine technology space where Vaxil Bio operates.
BioNTech
BNTX
Mkt Cap25.64B
BioNTech competes in the development of novel vaccines for a wide range of infectious diseases, aligning with Vaxil Bio's goals.
Pfizer
PFE
Mkt Cap159.36B
Pfizer develops and markets vaccines and therapeutics, directly competing with Vaxil Bio's vaccine development efforts.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its Janssen Pharmaceuticals division, develops vaccines, making it a competitor in the vaccine market.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline is a large pharmaceutical company with a significant vaccine portfolio, competing in the same market as Vaxil Bio.
Sanofi
SNY
Mkt Cap107.39B
Sanofi operates in the vaccine development space, making it a direct competitor to Vaxil Bio in the quest for innovative vaccines.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca is involved in the development and distribution of vaccines, competing with Vaxil Bio's vaccine development projects.
Inovio Pharmaceuticals
INO
Mkt Cap133.38M
Inovio Pharmaceuticals focuses on DNA-based vaccine development, competing with Vaxil Bio in the area of novel vaccine technologies.

About

Vaxil Bio Ltd. is a biotechnology firm dedicated to discovering and developing innovative therapeutic agents. Its foundation lies in a unique signal peptide-based platform, which it leverages to address critical health challenges, specifically infectious diseases and various cancers. The company's primary therapeutic candidate, ImMucin, has successfully advanced through Phase I/II clinical trials as a potential treatment for multiple myeloma. Beyond ImMucin, Vaxil Bio is actively developing a vaccine/treatment for tuberculosis, as well as a vaccine targeting coronavirus (COVID-19). Strategic alliances bolster its research efforts; Vaxil Bio collaborates with The Tel Aviv Sourasky Medical Center on a research initiative to create a peptide-based COVID-19 vaccine. Furthermore, it holds a Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Infectious Diseases to assess CorVax's efficacy in preventing COVID-19 in murine models. Established in 2006, the company's operations are based in Toronto, Canada.
Show more...
CEO
Mr. Gadi Levin B.Com., C.A., CPA, M.B.A.
Employees
3
Country
Canada
ISIN
CA92243L2066

Listings

OTC Link
US
VXLLF
V
CA
VXL.V

0 Comments

Share your thoughts

FAQ

What is Vaxil Bio stock price today?▼
The current price of VXLLF is $0.03 USD — it has decreased by -71.89% in the past 24 hours. Watch Vaxil Bio stock price performance more closely on the chart.
What is Vaxil Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Vaxil Bio stocks are traded under the ticker VXLLF.
Is Vaxil Bio stock price growing?▼
VXLLF stock has risen by +10.71% compared to the previous week, the month change is a -22.5% fall, over the last year Vaxil Bio has showed a +123.02% increase.
What is Vaxil Bio market cap?▼
Today Vaxil Bio has the market capitalization of 123,504
What were Vaxil Bio earnings last quarter?▼
VXLLF earnings for the last quarter are -0 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Vaxil Bio revenue for the last year?▼
Vaxil Bio revenue for the last year amounts to 0 USD.
What is Vaxil Bio net income for the last year?▼
VXLLF net income for the last year is 383,169.77 USD.
How many employees does Vaxil Bio have?▼
As of September 05, 2026, the company has 3 employees.
In which sector is Vaxil Bio located?▼
Vaxil Bio operates in the Health & Wellness sector.
When did Vaxil Bio complete a stock split?▼
The last stock split for Vaxil Bio was on May 15, 2025 with a ratio of 1:50.
Where is Vaxil Bio headquartered?▼
Vaxil Bio is headquartered in Toronto, Canada.